IL8 and Serum Soluble TRAIL Levels Following Anti-VEGF Monoclonal Antibody Treatment in Patients with Metastatic Colon Cancer


Kargi A., Yalcin A. D. , ERİN N., Savas B., Polat H. H. , Gorczynski R. M.

CLINICAL LABORATORY, cilt.58, ss.501-505, 2012 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 58
  • Basım Tarihi: 2012
  • Dergi Adı: CLINICAL LABORATORY
  • Sayfa Sayıları: ss.501-505

Özet

Background: Colorectal cancer is the third most common human cancer and the third leading cause of cancer related death. BevacizumAb is a humanized monoclonal antibody developed against vascular endothelial growth factor (VEGF) for the treatment of metastatic cancers.